Abstract
Cardiovascular atherosclerotic diseases remain leading causes of morbidity and mortality in the world. Despite the significant progress that has been made in the management of these diseases using medical, surgical and percutaneous therapies over the last three decades, there remains a significant population of patients who are not optimal candidates for surgical or percutaneous revascularization. Substantial research has focused on the administration of angiogenic growth factors, either as recombinant protein or by gene transfer, to promote the development of supplemental collateral blood vessels that will constitute endogenous bypass conduits around occluded native arteries, a strategy termed “therapeutic angiogenesis”. While many cytokines have angiogenic activity, the best studied both in animal models and clinical trials are vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF). This review will discuss gene transfer strategies for therapeutic angiogenesis in critical limb and myocardial ischemia.
Keywords: angiogenesis, gene transfer, myocardial ischemia, Cardiovascular atherosclerotic, percutaneous revascularization., vascular endothelial growth factor, vegf, fibroblast growth factor, therapeutic angiogenesis
Current Pharmaceutical Design
Title: Therapeutic Angiogenesis by Gene Transfer in Critical Limb and Myocardial Ischemia
Volume: 9 Issue: 13
Author(s): Peter Schratzberger, Rudolf Kirchmair, Peter R. Vale and Douglas W. Losordo
Affiliation:
Keywords: angiogenesis, gene transfer, myocardial ischemia, Cardiovascular atherosclerotic, percutaneous revascularization., vascular endothelial growth factor, vegf, fibroblast growth factor, therapeutic angiogenesis
Abstract: Cardiovascular atherosclerotic diseases remain leading causes of morbidity and mortality in the world. Despite the significant progress that has been made in the management of these diseases using medical, surgical and percutaneous therapies over the last three decades, there remains a significant population of patients who are not optimal candidates for surgical or percutaneous revascularization. Substantial research has focused on the administration of angiogenic growth factors, either as recombinant protein or by gene transfer, to promote the development of supplemental collateral blood vessels that will constitute endogenous bypass conduits around occluded native arteries, a strategy termed “therapeutic angiogenesis”. While many cytokines have angiogenic activity, the best studied both in animal models and clinical trials are vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF). This review will discuss gene transfer strategies for therapeutic angiogenesis in critical limb and myocardial ischemia.
Export Options
About this article
Cite this article as:
Schratzberger Peter, Kirchmair Rudolf, Vale R. Peter and Losordo W. Douglas, Therapeutic Angiogenesis by Gene Transfer in Critical Limb and Myocardial Ischemia, Current Pharmaceutical Design 2003; 9 (13) . https://dx.doi.org/10.2174/1381612033455062
DOI https://dx.doi.org/10.2174/1381612033455062 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Hyperpolarized Metabolic MR in the Study of Cardiac Function and Disease
Current Pharmaceutical Design The Role of Annexin A1 and Formyl Peptide Receptor 2/3 Signaling in Chronic Corticosterone-Induced Depression-Like behaviors and Impairment in Hippocampal-Dependent Memory
CNS & Neurological Disorders - Drug Targets Novel Therapeutic Targets for Phosphodiesterase 5 Inhibitors: current state-of-the-art on systemic arterial hypertension and atherosclerosis
Current Pharmaceutical Biotechnology Magnesium Lithospermate B Extracted from Salvia Miltiorrhiza, A Potential Substitute for Cardiac Glycosides
Mini-Reviews in Organic Chemistry Nuezhenide Exerts Anti-Inflammatory Activity through the NF-κB Pathway
Current Molecular Pharmacology Concerns and Hopes for Stem Cell Therapy in Cardiology: Focus on Endothelial Progenitor Cells
Cardiovascular & Hematological Disorders-Drug Targets Cardiac Adrenomedullin: Its Role in Cardiac Hypertrophy and Heart Failure
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Immune Checkpoint Inhibitors and Cardiac Toxicity: An Emerging Issue
Current Medicinal Chemistry Antiproliferative Strategies for the Treatment of Vascular Proliferative Disease
Current Vascular Pharmacology Optimal Oxygen Therapy in the Critically Ill Patient with Respiratory Failure
Current Respiratory Medicine Reviews Lectin-Like Oxidized Low Density Lipoprotein Receptor 1 (LOX-1) in Atherogenesis: A Brief Review
Current Medicinal Chemistry Depression in Coronary Heart Disease Patients: Etiological and Screening Issues
Current Psychiatry Reviews Cell Therapy for the Treatment of Chronic Ischemic Heart Disease
Current Pharmaceutical Design Metallothionein as a Scavenger of Free Radicals - New Cardioprotective Therapeutic Agent or Initiator of Tumor Chemoresistance?
Current Drug Targets Cardiac Role of the Transcription Factor NF-κB
Cardiovascular & Hematological Disorders-Drug Targets Nitric Oxide and the Regulation of Apoptosis in Tumour Cells
Current Pharmaceutical Design Testosterone and Cardioprotection Against Myocardial Ischemia
Cardiovascular & Hematological Disorders-Drug Targets Recent Advances in Small Animal Cardiac Magnetic Resonance Imaging
Current Cardiology Reviews Microparticles in Health and Disease: Small Mediators, Large Role?
Current Vascular Pharmacology Targeting Mitochondrial Oxidative Stress Through Lipoic Acid Synthase: A Novel Strategy to Manage Diabetic Cardiovascular Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry